Vaccines

December 21, 2020

HERO-TOGETHER study seeks health care workers who receive COVID-19 vaccine

Health care workers, who have been disproportionately affected by the COVID-19 pandemic, will be the first tier of Vanderbilt University Medical Center employees to receive vaccine to prevent SARS-CoV-2 infection.

The “orange team,” led by Buddy Creech, MD, director of the Vanderbilt Vaccine Research Program, assembles in the old Clinical Research Center space in Medical Center North on the first day of the phase 3 Moderna vaccine study this summer.
December 16, 2020

Coronavirus ‘crusaders’ spur VUMC research achievements

The development of the vaccines, monoclonal antibodies and antiviral drugs that ultimately will defeat COVID-19 wouldn’t have been possible had it not been for the unflagging and selfless efforts of a global army of research nurses, laboratory personnel, recruiters and other staff.

December 10, 2020

Exploiting viral vulnerabilities

The isolation of human monoclonal antibodies against dangerous viruses including EEEV, Hendra and Nipah could offer new ways to treat and prevent these infections.

James Crowe Jr., MD, and colleagues are exploring how the body’s immune system gears up to fight off infection.
December 1, 2020

Vanderbilt University Medical Center’s Crowe receives 2020 “Golden Goose” Award for COVID-19 research

James Crowe Jr., MD, a physician-scientist at Vanderbilt University Medical Center who has pioneered development of human monoclonal antibodies as potential treatments for viral diseases, has won a 2020 “Golden Goose” Award.

November 2, 2020

VUMC begins study of second COVID-19 vaccine

Vanderbilt University Medical Center has begun recruiting up to 250 participants for a Phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.

James Crowe Jr., MD, and colleagues are exploring how the body’s immune system gears up to fight off infection.
October 13, 2020

COVID-19 long-acting antibodies discovered by Vanderbilt University Medical Center move to phase 3 clinical trials

AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center and optimized by AstraZeneca.